TEICH ANDREW C

Director Andrew Teich buys 8,148 shares of REZI at $30.68; prior same-ticker buys showed 90-day win rate of 2 of 2.

Andrew Teich, a Director at Resideo, purchased 8,148 shares at $30.68 on 2025-11-10 for $249,975.55, increasing his holdings to 340,620 shares (+2.5%). This is his fourth open-market buy at Resideo within the past nine months. His prior same-ticker buys on 2025-08-29 and 2025-05-22 both showed positive 90-day returns (+21.5% and +58.6% respectively), demonstrating a consistent pattern of well-timed entry points at this ticker. However, the stock has declined -21.2% over the past 30 days and is -28.5% from its 52-week high of $44.50, suggesting the director is accumulating at a significantly reduced price level. His cross-ticker track record shows an average 90-day return of +29.9% across all tickers with a 100% win rate, indicating strong historical execution, though market conditions and fundamental valuations should be weighed independently.

Director Andrew C. Teich buys 29,460 REZI shares at $34.01; holdings jump to 332,472 (+9.7%); stock up 31.3% in 30 days, 61.8% in 90 days.

Director Teich purchased 29,460 shares at $34.01, just 0.5% below the 52-week high of $34.70, bringing his holdings to 332,472 shares. The timing follows strong momentum: REZI has gained 31.3% over 30 days and 61.8% over 90 days. Notably, Teich's two prior buys at this ticker (May 2025 and February 2025) both exhibited positive 90-day returns of +58.6% and +7.2%, establishing a pattern of well-timed accumulation at REZI specifically. While the current purchase occurs near a 52-week peak, the director's historical track record at this ticker and his continued accumulation (9.7% increase to holdings) during a period of sustained gains suggests ongoing confidence. However, the elevated P/E ratio of 54.56 against negative net income of $-825,000,000.00 in the latest quarter warrants caution on valuation fundamentals.

Director Teich buys 9,925 shares of ST at $25.19, increasing stake 31.8% to 41,117 shares amid 52-week price decline

Director Andrew C. Teich purchased 9,925 shares at $25.19 on 2025-05-23, expanding his total holdings by 31.8% from 31,192 to 41,117 shares. The transaction price sits 37.8% below the 52-week high of $42.30, yet Sensata's stock has climbed 23.2% over the prior 30 days and trades at a premium P/E of 31.33 relative to underlying fundamentals (annual revenue contracted 3.0% in the latest reporting period). Teich's cross-ticker track record shows 2 prior open-market buys with a 100% 90-day win rate, though that historical context does not necessarily predict outcomes in this specific name. The accumulation is material enough to warrant attention alongside the company's elevated valuation and recent negative revenue trends.

Director Teich buys 50,000 REZI shares at $20.20; holdings rise to 298,555 (+20.1%). Stock up 27.1% in 30 days.

Director Andrew C. Teich purchased 50,000 shares of Resideo at $20.20 on 2025-05-22, expanding his holdings by 20.1% to 298,555 shares post-transaction. The timing aligns with strong near-term momentum—the stock has gained 27.1% over the prior 30 days and 8.2% over 90 days, though it trades 25.5% below its 52-week high of $27.75. Teich's cross-ticker buy record shows a 100% win rate at the 90-day mark, and his prior REZI purchase on 2025-02-26 returned +7.2% over 90 days, suggesting a pattern of well-timed accumulation. The company's $1.8B quarterly revenue, 8.3% annual growth, and $3.1B market cap provide a material-scale business backdrop, though the elevated 39.0 P/E multiple and thin $6.0M net income warrant attention to earnings quality.

Director Teich buys 18,154 shares at $19.29 as REZI declines 29.3% in 90 days

Director Andrew C. Teich purchased 18,154 shares at $19.29, increasing his holdings to 239,768 shares (+8.2% net change). The purchase occurs amid material price pressure: REZI has fallen 29.3% over the past 90 days and is -30.8% from its 52-week high of $27.75, currently trading at $19.21. The company maintains reasonable fundamentals with $1.8B in latest-quarter revenue (+8.3% annual growth) and $20.0M in net income, though the P/E of 34.93 remains elevated. This insider buy coincides with significant recent deterioration in the stock price, though no prior transaction history or trading plan flags are provided to contextualize this purchase against the director's past activity.